

## Disclosures

### Personal Commercial (15)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Amgen Inc.	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Arrowhead	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
AstraZeneca Pharmaceuticals	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Bayer Healthcare Pharmaceuticals	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Boehringer Ingelheim Pharmaceuticals, Inc	Consultant Fees/Honoraria	Significant (>= \$5,000)	Prevention
Edwards Lifesciences	Consultant Fees/Honoraria	Modest (< \$5,000)	Valvular Heart Disease
Eli Lilly and Company	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Esperion	Consultant Fees/Honoraria	Significant (>= \$5,000)	Prevention
Ionis	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Medtronic	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention Valvular Heart Disease
Merck & Co., Inc.	Consultant Fees/Honoraria	Significant (>= \$5,000)	Prevention
New Amsterdam	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Novartis Corporation	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Novo Nordisk Inc.	Consultant Fees/Honoraria	Significant (>= \$5,000)	Prevention
Zoll	Consultant Fees/Honoraria	Modest (< \$5,000)	Other

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (4)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
American Heart Association † none	Research/Research Grants	Significant (>= \$5,000)	Prevention
American Journal of Preventive Cardiology † none	Other - Editor in Chief of a journal	Significant (>= \$5,000)	Prevention
National Institutes of Health	Research/Research Grants	Significant (>= \$5,000)	Prevention General Cardiology
National Institutes of Health	Research/Research Grants	Significant (>= \$5,000)	Other

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

## Agreement

**Certified Education Attestation** | Signed on 4/21/2025

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>*

**Confidentiality, Disclosure and Assignment Agreement** | Signed on 4/21/2025

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>*

**Embargo** | Signed on 4/21/2025

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>*

**On-Going Obligation Agreement** | Signed on 4/21/2025

---

## **ACC and Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.